To our knowledge, no predictive studies have been realised to identify K-Ras mutated subclones in NSCLC, but the presence of such mutated subclones could explain some cases of secondary EGFR-targeted therapy resistance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.